Experience and levels of satisfaction with the levonorgestrel-releasing intrauterine system in China: a prospective multicenter survey

Figures & data

Figure 1 Patients’ recall of the standardized information on Mirena^® (Bayer Healthcare Pharmaceuticals, Whippany, NJ, USA) they had received during preinsertion counseling.

Abbreviation: IUD, intrauterine device; Cu, copper.

Table 1 Baseline characteristics of the respondents (n=1,021)

Characteristic	%
Age, years
<30	16
30–40	59
>40	25
City groupa
1	34
2	34
3	32
Number of children per respondent
No children	8
One child	76
More than one child	16
Respondents planning on having children
Yes	11
No	76
Do not know	13
Previous contraceptive methods
Condoms	83
Oral contraceptives	32
Copper IUD	23
Natural methods	23
Mirena^®	3
Othersb	4
Mirena implantation time
After/during normal menstrual period	56
After abortion	32
After giving birth	2
Other	10

Notes:

a City group 1, health care expenditure in 2006 > CNY 5 million; city group 2, health care expenditure in 2006 CNY 2.5–5 million; city group 3, health care expenditure in 2006 < CNY 2.5 million.

b Chemical methods, female/male sterilization, and injections/implants. Mirena^® (Bayer Healthcare Pharmaceuticals, Whippany, NJ, USA).

Abbreviations: IUD, intrauterine device; CNY, Chinese Yuan.

Figure 2 Reasons for inserting Mirena^® (Bayer Healthcare Pharmaceuticals, Whippany, NJ, USA).

Abbreviation: yrs, years.

Figure 3 Rates of satisfaction with Mirena^® (Bayer Healthcare Pharmaceuticals, Whippany, NJ, USA) at the second follow-up visit.

Figure 4 Agreement levels with the information provided on the attributes of Mirena^® (Bayer Healthcare Pharmaceuticals, Whippany, NJ, USA).

Notes: (A) at the first and second follow-up visits, (B) by city group, and (C) by respondent age.

Figure 5 Percentages of respondents at the second follow-up visit who would recommend Mirena^® (Bayer Healthcare Pharmaceuticals, Whippany, NJ, USA) to their friends.